199 related articles for article (PubMed ID: 24346160)
1. The dual functions of YAP-1 to promote and inhibit cell growth in human malignancy.
Wang H; Du YC; Zhou XJ; Liu H; Tang SC
Cancer Metastasis Rev; 2014 Mar; 33(1):173-81. PubMed ID: 24346160
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
3. Association between YAP expression in neoplastic and non-neoplastic breast tissue with arsenic urinary levels.
Michel-Ramirez G; Recio-Vega R; Ocampo-Gomez G; Palacios-Sanchez E; Delgado-Macias M; Delgado-Gaona M; Lantz RC; Gandolfi J; Gonzalez-Cortes T
J Appl Toxicol; 2017 Oct; 37(10):1195-1202. PubMed ID: 28524356
[TBL] [Abstract][Full Text] [Related]
4. RARγ Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo-Yap Pathway.
Guo PD; Lu XX; Gan WJ; Li XM; He XS; Zhang S; Ji QH; Zhou F; Cao Y; Wang JR; Li JM; Wu H
Cancer Res; 2016 Jul; 76(13):3813-25. PubMed ID: 27325643
[TBL] [Abstract][Full Text] [Related]
5. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
[TBL] [Abstract][Full Text] [Related]
6. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
7. YAP Subcellular Localization and Hippo Pathway Transcriptome Analysis in Pediatric Hepatocellular Carcinoma.
LaQuaglia MJ; Grijalva JL; Mueller KA; Perez-Atayde AR; Kim HB; Sadri-Vakili G; Vakili K
Sci Rep; 2016 Sep; 6():30238. PubMed ID: 27605415
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Rac GTPase Activating Protein 1 Contributes to Proliferation of Cancer Cells by Reducing Hippo Signaling to Promote Cytokinesis.
Yang XM; Cao XY; He P; Li J; Feng MX; Zhang YL; Zhang XL; Wang YH; Yang Q; Zhu L; Nie HZ; Jiang SH; Tian GA; Zhang XX; Liu Q; Ji J; Zhu X; Xia Q; Zhang ZG
Gastroenterology; 2018 Oct; 155(4):1233-1249.e22. PubMed ID: 30009820
[TBL] [Abstract][Full Text] [Related]
9. Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion.
Vlahov N; Scrace S; Soto MS; Grawenda AM; Bradley L; Pankova D; Papaspyropoulos A; Yee KS; Buffa F; Goding CR; Timpson P; Sibson N; O'Neill E
Curr Biol; 2015 Dec; 25(23):3019-34. PubMed ID: 26549256
[TBL] [Abstract][Full Text] [Related]
10. YAP knockdown inhibits proliferation and induces apoptosis of human prostate cancer DU145 cells.
Jin X; Zhao W; Zhou P; Niu T
Mol Med Rep; 2018 Mar; 17(3):3783-3788. PubMed ID: 29286134
[TBL] [Abstract][Full Text] [Related]
11. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma.
Ahn EY; Kim JS; Kim GJ; Park YN
Mol Cancer Res; 2013 Jul; 11(7):748-58. PubMed ID: 23594797
[TBL] [Abstract][Full Text] [Related]
12. Fat4 suppression induces Yap translocation accounting for the promoted proliferation and migration of gastric cancer cells.
Ma L; Cui J; Xi H; Bian S; Wei B; Chen L
Cancer Biol Ther; 2016; 17(1):36-47. PubMed ID: 26575609
[TBL] [Abstract][Full Text] [Related]
13. WWC2 is an independent prognostic factor and prevents invasion via Hippo signalling in hepatocellular carcinoma.
Zhang Y; Yan S; Chen J; Gan C; Chen D; Li Y; Wen J; Kremerskothen J; Chen S; Zhang J; Cao Y
J Cell Mol Med; 2017 Dec; 21(12):3718-3729. PubMed ID: 28815883
[TBL] [Abstract][Full Text] [Related]
14. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance.
Wang DY; Wu YN; Huang JQ; Wang W; Xu M; Jia JP; Han G; Mao BB; Bi WZ
Chin J Cancer; 2016 May; 35():47. PubMed ID: 27206784
[TBL] [Abstract][Full Text] [Related]
15. Hippo signaling dysfunction induces cancer cell addiction to YAP.
Han H; Yang B; Nakaoka HJ; Yang J; Zhao Y; Le Nguyen K; Bishara AT; Mandalia TK; Wang W
Oncogene; 2018 Dec; 37(50):6414-6424. PubMed ID: 30068939
[TBL] [Abstract][Full Text] [Related]
16. Hippo signaling promotes JNK-dependent cell migration.
Ma X; Wang H; Ji J; Xu W; Sun Y; Li W; Zhang X; Chen J; Xue L
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1934-1939. PubMed ID: 28174264
[TBL] [Abstract][Full Text] [Related]
17. Yes-associated protein (YAP) functions as a tumor suppressor in breast.
Yuan M; Tomlinson V; Lara R; Holliday D; Chelala C; Harada T; Gangeswaran R; Manson-Bishop C; Smith P; Danovi SA; Pardo O; Crook T; Mein CA; Lemoine NR; Jones LJ; Basu S
Cell Death Differ; 2008 Nov; 15(11):1752-9. PubMed ID: 18617895
[TBL] [Abstract][Full Text] [Related]
18. Deubiquitinase YOD1: the potent activator of YAP in hepatomegaly and liver cancer.
Kim Y; Jho EH
BMB Rep; 2017 Jun; 50(6):281-282. PubMed ID: 28502290
[TBL] [Abstract][Full Text] [Related]
19. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.
Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC
Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596
[TBL] [Abstract][Full Text] [Related]
20. PTEN lipid phosphatase inactivation links the hippo and PI3K/Akt pathways to induce gastric tumorigenesis.
Xu W; Yang Z; Xie C; Zhu Y; Shu X; Zhang Z; Li N; Chai N; Zhang S; Wu K; Nie Y; Lu N
J Exp Clin Cancer Res; 2018 Aug; 37(1):198. PubMed ID: 30134988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
